Anne Li Feburary 11th, 2017
Cancer Research Technology, Cancer Research UK’s commercial arm, Tusk Therapeutics, an immuno-oncology company, and UCL(University College London) have signed a licence and collaboration agreement to research, develop and commercialise an antibody-based therapeutic against a target that plays a key role in immune suppression in cancer. Under the terms of the agreement, Tusk Therapeutics will receive an exclusive world-wide licence from CRT to develop and commercialise therapeutic antibodies against the target, originating from the Cancer Research UK-funded research of Dr Sergio Quezada and Professor Karl Peggs at UCL. In return, CRT will receive an upfront payment, future success-based milestones and royalty payments, which will be shared with UCL.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-02-07-cancer-research-technology-ucl-and-tusk-therapeutics-join-forces-to-develop-cancer-immunotherapies